The association between gut microbiome affecting concomitant medication and the effectiveness of immunotherapy in patients with stage IV NSCLC

Several observational studies suggested that gut microbiome-affecting-medication impairs the effectiveness of immunotherapy in patients with metastatic non-small-cell lung cancer (NSCLC). We postulated that if the effectiveness of immunotherapy is affected by drug-related changes of the microbiome,...

Descripción completa

Detalles Bibliográficos
Autores principales: Verschueren, M. V., van der Welle, C. M. Cramer -, Tonn, M., Schramel, F. M. N. H., Peters, B. J. M., van de Garde, E. M. W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8640057/
https://www.ncbi.nlm.nih.gov/pubmed/34857829
http://dx.doi.org/10.1038/s41598-021-02598-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8640057/
https://www.ncbi.nlm.nih.gov/pubmed/34857829
http://dx.doi.org/10.1038/s41598-021-02598-0

Ejemplares similares